Quick Answer
Protalix BioTherapeutics, Inc. reported Earnings Per Share Diluted of $0.08 (loss) per share for the year ending 2025.
- Protalix BioTherapeutics, Inc. showed a decrease of -300.0% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from Protalix BioTherapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 18, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 7 years of available data (2019 to 2025), Protalix BioTherapeutics, Inc.'s Earnings Per Share Diluted has grown by 93.5%.
- Historical annual values: Fiscal year 2025: $0.08 (loss) per share | Fiscal year 2024: $0.04 per share | Fiscal year 2023: $0.09 per share | Fiscal year 2022: $0.31 (loss) per share | Fiscal year 2021: $0.62 (loss) per share | Fiscal year 2020: $0.22 (loss) per share | Fiscal year 2019: $1.23 (loss) per share.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: